Incyte | INCY - Current Liabilities


Incyte reported $1.31B in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 361.44M 55.91M Jun/2026
Agenus USD 231.82M 17.42M Jun/2026
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Amgen USD 25.5B 547M Jun/2026
BioCryst Pharmaceuticals USD 208.85M 13.46M Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
Exelixis USD 361.93M 9.05M Jun/2026
Gilead Sciences USD 11.02B 1.54B Jun/2026
Incyte USD 1.31B 177.55M Jun/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
MacroGenics USD 108.82M 12.88M Jun/2026
Merck USD 27.73B 786M Jun/2026
Moderna USD 2.53B 139M Jun/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Novartis USD 31.75B 374M Jun/2026
Novartis USD 31.37B 4.1B Mar/2026
Pfizer USD 32.65B 1.7B Jun/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Sarepta Therapeutics USD 502.91M 3.74M Jun/2026
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026